TDP-43 pathology in Alzheimer's disease, dementia with Lewy bodies and ageing
- PMID: 27495267
- PMCID: PMC8029292
- DOI: 10.1111/bpa.12424
TDP-43 pathology in Alzheimer's disease, dementia with Lewy bodies and ageing
Abstract
Intracellular inclusions consisting of TAR DNA binding protein-43 (TDP-43 pathology) are present in up to 57% of Alzheimer's disease (AD) cases and follow a distinct topographical pattern of progression described in the TDP-43 in AD staging scheme. This scheme has not been applied to the assessment of TDP-43 pathology in dementia with Lewy bodies (DLB) and aged controls. We investigated TDP-43 pathology prevalence and severity in AD, DLB, mixed AD/DLB (Mx AD/DLB) and aged controls. One hundred and nineteen human post-mortem brains were included, neuropathologically diagnosed as AD: 46, DLB: 15, Mx AD/DLB: 19 and aged controls: 39. Paraffin sections inclusive of the amygdala, hippocampus, striatum and neocortex were immunohistochemically stained with antibodies against phosphorylated TDP-43 and staged according to the TDP-43 in AD staging scheme. TDP-43 pathology was present in all groups: AD: 73.9%, DLB: 33.3%, Mx AD/DLB: 52.6% and controls: 17.9%. Prevalence of TDP-43 pathology was significantly higher in AD and Mx AD/DLB compared to controls. In controls, higher age at death was associated with prevalence of TDP-43 pathology and higher TDP-43 in AD stage, suggesting that this type of TDP-43 pathology may partly be an age-associated phenomenon. Significantly higher prevalence of TDP-43 pathology in the AD group indicates that AD pathology possibly triggers and aggravates TDP-43 pathology. The validity of the TDP-43 in AD staging scheme is not limited to AD and should be applied to assess TDP-43 pathology in post mortem brains of aged individuals to further elucidate the role of TDP-43 pathology in age associated neurodegeneration.
Keywords: Alzheimer's disease; Lewy body diseases; TDP-43; ageing; dementia with Lewy bodies; hippocampal sclerosis; mixed Alzheimer's disease and dementia with Lewy bodies.
© 2016 International Society of Neuropathology.
Conflict of interest statement
The authors declare they have no conflict of interest.
Figures


Similar articles
-
Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies.Brain Res. 2007 Dec 12;1184:284-94. doi: 10.1016/j.brainres.2007.09.048. Epub 2007 Oct 25. Brain Res. 2007. PMID: 17963732
-
Neuropathologically mixed Alzheimer's and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes.Acta Neuropathol. 2015 May;129(5):729-48. doi: 10.1007/s00401-015-1406-3. Epub 2015 Mar 11. Acta Neuropathol. 2015. PMID: 25758940
-
Phosphorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies.Acta Neuropathol. 2009 Feb;117(2):125-36. doi: 10.1007/s00401-008-0480-1. Epub 2009 Jan 13. Acta Neuropathol. 2009. PMID: 19139911
-
The Differential Effects of Alzheimer's Disease and Lewy Body Pathology on Cognitive Performance: a Meta-analysis.Neuropsychol Rev. 2017 Mar;27(1):1-17. doi: 10.1007/s11065-016-9334-0. Epub 2016 Nov 22. Neuropsychol Rev. 2017. PMID: 27878426 Review.
-
Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.J Neural Transm (Vienna). 2018 Apr;125(4):615-650. doi: 10.1007/s00702-017-1821-9. Epub 2017 Dec 8. J Neural Transm (Vienna). 2018. PMID: 29222591 Review.
Cited by
-
Comorbid neuropathological diagnoses in early versus late-onset Alzheimer's disease.Brain. 2021 Aug 17;144(7):2186-2198. doi: 10.1093/brain/awab099. Brain. 2021. PMID: 33693619 Free PMC article.
-
Phosphorylated TDP-43 Staging of Primary Age-Related Tauopathy.Neurosci Bull. 2019 Apr;35(2):183-192. doi: 10.1007/s12264-018-0300-0. Epub 2018 Oct 31. Neurosci Bull. 2019. PMID: 30382507 Free PMC article.
-
Seeding the aggregation of TDP-43 requires post-fibrillization proteolytic cleavage.Nat Neurosci. 2023 Jun;26(6):983-996. doi: 10.1038/s41593-023-01341-4. Epub 2023 May 29. Nat Neurosci. 2023. PMID: 37248338 Free PMC article.
-
New Therapeutic Avenue for ALS: Avoiding a Fatal Encounter of TDP-43 at the Mitochondria.Mol Ther. 2017 Jan 4;25(1):10-11. doi: 10.1016/j.ymthe.2016.12.001. Epub 2017 Jan 4. Mol Ther. 2017. PMID: 28129105 Free PMC article. No abstract available.
-
TDP-43 mediated blood-brain barrier permeability and leukocyte infiltration promote neurodegeneration in a low-grade systemic inflammation mouse model.J Neuroinflammation. 2020 Sep 26;17(1):283. doi: 10.1186/s12974-020-01952-9. J Neuroinflammation. 2020. PMID: 32979923 Free PMC article.
References
-
- Arai T, Mackenzie IR, Hasegawa M, Nonoka T, Niizato K, Tsuchiya K et al (2009) Phosphorylated TDP‐43 in Alzheimer's disease and dementia with Lewy bodies. Acta Neuropathol 117:125–136. - PubMed
-
- Braak H, Braak E (1991) Neuropathological stageing of Alzheimer‐related changes. Acta Neuropathol 82:239–259. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical